The efficient spread of malaria from infected humans to mosquitoes is a major challenge for
malaria elimination initiatives. Gametocytes are the only Plasmodium life stage infectious to …

Malaria is a vector-borne disease of global importance, with the vast majority of its life-
threatening cases caused by infection with Plasmodium falciparum parasites. Repeated …

Summary Pfs230 domain 1 (Pfs230D1) is an advanced malaria transmission-blocking
vaccine antigen demonstrating high functional activity in clinical trials. However, the …

Background Malaria elimination requires interruption of the highly efficient transmission of
Plasmodium parasites by mosquitoes. TB31F is a humanised monoclonal antibody that …

Malaria transmission-blocking vaccines (TBVs) aim to induce antibodies that interrupt
malaria parasite development in the mosquito, thereby blocking onward transmission, and …

Malaria caused by the Plasmodium vivax parasite is a major global health burden. Immunity
against blood-stage infection reduces parasitemia and disease severity. Duffy-binding …

A malaria vaccine that blocks parasite transmission from human to mosquito would be a
powerful method of disrupting the parasite lifecycle and reducing the incidence of disease in …

Development of effective malaria vaccines requires delivery platforms to enhance the
immunogenicity and efficacy of the target antigens. This is particularly challenging for …

Abstract Proteins Pfs230 and Pfs48/45 are Plasmodium falciparum transmission-blocking
(TB) vaccine candidates that form a membrane-bound protein complex on gametes. The …

An effective malaria vaccine remains a global health priority and vaccine immunogens
which prevent transmission of the parasite will have important roles in multi-component …